Fig. 1: CheckMate 77T nodal status analysis population. | Nature Cancer

Fig. 1: CheckMate 77T nodal status analysis population.

From: Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

Fig. 1

Patients were enrolled between November 2019 and April 2022 and had a median follow-up of 25.4 months (range, 15.7–44.2) as of the 6 September 2023 database lock for this analysis. The denominators used to calculate percentages were based on the number of patients in each previous cohort. The superscript ‘a’ indicates that the enrollment of patients with stage III N3 NSCLC was considered a protocol deviation.

Source data

Back to article page